Annexon, Inc.
Close on Oct 19, 2026
- Market cap
- $806.02M
- P/E (TTM)
- –
- Dividend yield
- 0.00%
Earnings
Next report expected Nov 9, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 12, 2026 | Before market open | – | $-0.28 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 7, 2026 | During market hours | – | $-0.23 | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 30, 2026 | During market hours | – | $-0.28 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 10, 2025 | During market hours | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | During market hours | – | $-0.34 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 12, 2025 | During market hours | – | $-0.37 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 3, 2025 | During market hours | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | During market hours | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 12, 2024 | Before market open | – | $-0.23 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 13, 2024 | During market hours | – | $-0.21 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 26, 2024 | During market hours | – | $-0.36 | – |
Press releases
Announcements Annexon filed with the SEC
Annexon Reports Second Quarter 2026 Financial Results, Business Updates and Key Anticipated Milestones
Results of operations · Other events · EX-99.1 to Form 8-K
Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy with Addition of Month 24 Dual Primary
Results of operations · Other events · EX-99.2 to Form 8-K
Annexon Appoints Renowned Retinal Surgeon and Biotechnology Entrepreneur Mark S. Blumenkranz, M.D.,
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive
Other events · EX-99.1 to Form 8-K
Annexon Secures Strategic Credit Facility for up to $200 Million from Oxford Finance
Material agreement · New financial obligation · Other events · EX-99.1 to Form 8-K
Annexon Reports First Quarter 2026 Financial Results, Portfolio Progress and Key Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Annexon Reports Fourth Quarter and Year-End 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
MORGAN HEALTHCARE CONFERENCE JANUARY 2026 Nasdaq: ANNX ©2025 Annexon, Inc. All rights reserved
Regulation FD disclosure · EX-99.1 to Form 8-K
Annexon Accelerating Next Generation Targeted Immunotherapy Platform for
Other events · EX-99.1 to Form 8-K
Annexon Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants
Material agreement · Other events · EX-99.1 to Form 8-K
Annexon Announces Closing of Public Offering and Full Exercise of Underwriters’
Material agreement · Other events · EX-99.2 to Form 8-K
Annexon Reports Third Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Annexon Reports Second Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Annexon Reports First Quarter 2025 Financial Results, Portfolio Progress and Key Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Annexon Reports Fourth Quarter and Year-End 2024 Financial Results, Portfolio Progress and Key Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Annexon Provides 2025 Outlook with Strong Momentum Accelerating into Breakthrough Year
Other events · EX-99.1 to Form 8-K
Annexon Expands Board of Directors with Appointment of Commercial Executive William BJ Jones
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
Annexon Reports Third Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Annexon Presents Phase 2 Vision Preservation Data with ANX007 in Dry AMD Patients
Other events · EX-99.1 to Form 8-K
Annexon Reports Second Quarter 2024 Portfolio and Financial Results, and Key Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Annexon Provides Update on ARCHER II Global Registrational Program in Geographic Atrophy
Other events · EX-99.1 to Form 8-K
Annexon Presented Additional Positive Phase 3 Results for ANX005
Other events · EX-99.1 to Form 8-K
Annexon Announces Pricing of $125 Million Underwritten Public Offering
Material agreement · Other events · EX-99.1 to Form 8-K
Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
‐ oking” statements about Annexon, Inc. and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts, including statements regarding our clinical and preclinical programs,
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in
Other events · EX-99.1 to Form 8-K
Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
Results of operations · EX-99.1 to Form 8-K
Guillain-Barré Syndrome: A Focus on its Serious Unmet Need and
Regulation FD disclosure · EX-99.1 to Form 8-K
Annexon Outlines 2024 Priorities with Late-Stage Clinical Milestones Across Upstream Complement Portfolio
Regulation FD disclosure · EX-99.1 to Form 8-K
Annexon Announces Pricing of $125.0 Million Underwritten Public Offering of Common Stock
Material agreement · Other events · EX-99.1 to Form 8-K
Annexon Outlines Global Registrational Program for ANX007 in Geographic
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Annexon Reports Phase 1 Results for ANX1502, Its Oral Small Molecule Inhibitor of the Classical
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
ANX007 Phase 3 GA Program December
Regulation FD disclosure · Other events · EX-99.3 to Form 8-K
Annexon Reports Significant Progress with its Priority Programs and Third Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
ANNEXON RECEIVES PRIME DESIGNATION FROM THE EMA FOR ANX007 FOR THE TREATMENT OF GEOGRAPHIC ATROPHY
Other events · EX-99.1 to Form 8-K
ANNEXON ANNOUNCES CLINICAL AND REGULATORY PROGRESS FOR ANX005 PIVOTAL
Other events · EX-99.1 to Form 8-K
Annexon Highlights Recent Pipeline and Business Progress and Reports Second Quarter 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K